OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Liquid and lyophilized forms and preparing for the large capacity present challenges.
April 21, 2021
Post-inspection report reveals nine sanitary and process problems at Bayview, Md., facility.
April 19, 2021
Pending a completed FDA inspection, Emergent BioSolutions halts manufacture of vaccine drug substance at Maryland facility.
April 09, 2021
Even before Emergent disclosed that it had to discard 15 million doses of the J&J vaccine drug substance, FDA inspectors had uncovered multiple deficiencies and quality control issues.
April 05, 2021
Following a manufacturing mix-up, J&J will extend its oversight at Emergent’s Maryland facility; AstraZeneca manufacturing to relocate.
April 01, 2021
The availability of materials is a critical factor when it comes to vaccine capacity.
March 30, 2021
SGS is supporting Selecta Biosciences and Asklepios BioPharmaceutical with the Phase I dose-escalation trial of SEL-3999, an AAV8 vector capsid containing no transgene with ImmTOR.
March 01, 2021
Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
February 22, 2021
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.